This IA for patients with DCM was first reported in an uncontrolled pilot study by Wallukat et al. [23], who showed that this technique efficiently removed circulating antibodies directed against the β1-AR. This evidence concerns the gene ADRB1 and familial dilated cardiomyopathy.